Table 1.
Overexpression of serotonin and dopamine receptors in different tumour types determined with functional genomic mRNA analysis
| Percentage overexpression (%) | ||||
|---|---|---|---|---|
| Tumor type (N) | 5-HTR1B | 5-HTR2B | DRD1 | DRD2 |
| Breast cancer | ||||
| ER-/Her2+ (455) | 6.6 | 3.5 | 2.0 | 1.1 |
| ER+/Her2- (1,678) | 3.4 | 4.5 | 1.0 | 0.6 |
| ER+/Her2+ (506) | 3.8 | 4.5 | 1.4 | 0.6 |
| TNBC (737) | 7.3 | 3.5 | 0.7 | 1.2 |
| CNS malignancies | ||||
| Anaplastic astrocytoma (36) | 5.6 | 8.3 | 2.8 | 0.0 |
| Anaplastic oligodendroglioma (26) | 3.8 | 0.0 | 0.0 | 0.0 |
| Astrocytoma (24) | 4.2 | 25.0 | 4.2 | 12.5 |
| Ependymoma (156) | 1.3 | 0.0 | 29.5 | 0.6 |
| Glioblastoma (389) | 1.8 | 2.1 | 1.3 | 0.3 |
| Medulloblastoma (148) | 2.7 | 4.1 | 0.7 | 6.8 |
| Meningioma (122) | 3.8 | 7.6 | 0.0 | 2.5 |
| Oligodendroglioma (23) | 4.3 | 13.0 | 4.3 | 4.3 |
| Pilocytic astrocytoma (135) | 0.7 | 3.0 | 0.0 | 0.0 |
| Endocrine malignancies | ||||
| Adrenal neuroblastoma (96) | 4.2 | 5.2 | 1.0 | 25.0 |
| Adrenocortical carcinoma (20) | 0.0 | 10.0 | 0.0 | 0.0 |
| Anaplastic thyroid carcinoma (21) | 0.0 | 14.3 | 0.0 | 0.0 |
| Papillary thyroid carcinoma (51) | 2.0 | 7.8 | 0.0 | 0.0 |
| Gastrointestinal malignancies | ||||
| Colorectal cancer (2,710) | 1.3 | 4.3 | 0.9 | 3.7 |
| Esophageal adenocarcinoma (41) | 4.9 | 14.6 | 7.3 | 0.0 |
| Esophageal squamous cell carcinoma (56) | 0.0 | 3.6 | 0.0 | 0.0 |
| Gastric cancer (332) | 3.9 | 12.0 | 7.8 | 0.6 |
| Hepatocellular carcinoma (364) | 3.3 | 19.5 | 6.0 | 0.0 |
| Pancreatic cancer (81) | 0.0 | 8.6 | 1.2 | 0.0 |
| Genitourinary malignancies | ||||
| Bladder cancer (39) | 5.1 | 7.7 | 7.7 | 2.6 |
| Chromophobe renal cancer (37) | 0.0 | 0.0 | 0.0 | 2.7 |
| Clear cell renal cancer (225) | 5.8 | 7.6 | 0.9 | 1.8 |
| Papillary renal cancer (37) | 0.0 | 0.0 | 0.0 | 0.0 |
| Prostate cancer (308) | 3.6 | 5.2 | 0.6 | 1.9 |
| Gynaecological malignancies | ||||
| Cervical cancer (62) | 1.6 | 6.5 | 0.0 | 3.2 |
| Ovarian cancer (187) | 0.5 | 3.7 | 0.5 | 0.0 |
| Head and neck cancer | ||||
| HNSCC (344) | 4.9 | 0.6 | 2.0 | 1.2 |
| Nasopharyngeal carcinoma (42) | 16.7 | 11.9 | 0.0 | 2.4 |
| Lung cancer | ||||
| Adenocarcinoma (1,019) | 1.6 | 7.8 | 2.7 | 0.5 |
| Squamous cell carcinoma (405) | 0.2 | 2.7 | 1.5 | 0.5 |
| Small cell lung cancer (103) | 1.0 | 15.5 | 4.9 | 8.7 |
| Melanoma | ||||
| Cutaneous (398) | 3.8 | 9.0 | 0.0 | 1.3 |
| Uveal (106) | 2.8 | 55.7 | 2.8 | 0.9 |
| Sarcoma | ||||
| Ewing’s sarcoma (26) | 3.8 | 0.0 | 0.0 | 3.8 |
| Leiomyosarcoma (60) | 1.7 | 6.7 | 5.0 | 5.0 |
| Liposarcoma (76) | 3.9 | 19.7 | 1.3 | 1.3 |
| Osteosarcoma (26) | 0.0 | 15.4 | 0.0 | 0.0 |
| Primitive neuroectodermal tumor (22) | 4.5 | 0.0 | 0.0 | 4.5 |
| Synovial sarcoma (34) | 0.0 | 0.0 | 20.6 | 0.0 |
| Undifferentiated sarcoma (95) | 1.1 | 9.5 | 1.1 | 0.0 |
N; number, 5-HTR1B; serotonin receptor 1B, 5-HTR2B; serotonin receptor 2B, DRD1; dopamine receptor D1, DRD2; dopamine receptor D2, ER; estrogen receptor, Her2; human epidermal growth factor receptor 2, TNBC: triple negative breast cancer, CNS; central nervous system, HNSCC; head and neck squamous cell carcinoma